See more : PT Astra International Tbk (PTAIF) Income Statement Analysis – Financial Results
Complete financial analysis of EuBiologics Co., Ltd. (206650.KQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of EuBiologics Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- The Russian Public Joint-Stock Commercial Roads Bank (Public joint-stock company) (RDRB.ME) Income Statement Analysis – Financial Results
- Intergis Co., Ltd (129260.KS) Income Statement Analysis – Financial Results
- ArcelorMittal S.A. (ARRD.DE) Income Statement Analysis – Financial Results
- Better Home & Finance Holding Company (BETR) Income Statement Analysis – Financial Results
- Shanghai Laiyifen Co.,Ltd (603777.SS) Income Statement Analysis – Financial Results
EuBiologics Co., Ltd. (206650.KQ)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: http://www.eubiologics.com
About EuBiologics Co., Ltd.
EuBiologics Co., Ltd., a biopharmaceutical company, develops and supplies vaccines for epidemics and antibiotic resistance in South Korea. It offers Euvchol, an oral cholera prevention vaccine; and CRM197, a diphtheria toxin mutant vaccine. The company also provides customized services for mammalian cell and microbial cell derived biopharmaceuticals in accordance with the clients' project stages, including cell line development, GMP production, validation, and the regulatory support; and operates facilities that manufacture protein-based therapeutics and antibodies. It specializes in manufacturing a range of mammalian cell and microbial cell derived biopharmaceuticals, including recombinant biological products and antibody therapeutics. In addition, the company offers process, formulation, and analytical method development, as well as licensing consulting services; and contract testing services that include lot release, stability, raw material, and method validation testing services. The company was founded in 2010 and is based in Seoul, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 69.37B | 55.47B | 39.38B | 28.49B | 33.07B | 24.89B | 11.57B | 4.84B | 1.60B |
| Cost of Revenue | 35.40B | 33.25B | 25.13B | 22.37B | 14.32B | 13.35B | 12.27B | 9.20B | 1.96B |
| Gross Profit | 33.96B | 22.22B | 14.26B | 6.12B | 18.75B | 11.54B | -702.01M | -4.35B | -356.89M |
| Gross Profit Ratio | 48.96% | 40.06% | 36.20% | 21.50% | 56.70% | 46.35% | -6.07% | -89.83% | -22.27% |
| Research & Development | 17.88B | 15.16B | 15.64B | 8.09B | 3.95B | 2.90B | 1.20B | 717.49M | 1.16B |
| General & Administrative | 1.52B | 1.43B | 663.32M | 507.46M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 1.91B | 1.75B | 936.54M | 775.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.43B | 10.61B | 5.74B | 3.91B | 4.85B | 3.28B | 2.42B | 1.81B | 1.19B |
| Other Expenses | 5.01B | -223.54M | -99.44M | -80.68M | -136.39M | -45.37M | -579.71M | -32.40M | -15.13M |
| Operating Expenses | 26.32B | 25.99B | 21.49B | 12.09B | 8.94B | 6.23B | 4.19B | 2.56B | 2.36B |
| Cost & Expenses | 61.67B | 59.24B | 46.61B | 34.45B | 23.26B | 19.58B | 16.46B | 11.76B | 4.32B |
| Interest Income | 164.68M | 230.76M | 356.52M | 106.69M | 71.28M | 136.37M | 133.37M | 14.98M | 7.51M |
| Interest Expense | 1.05B | 508.29M | 838.11M | 2.14B | 324.94M | 46.12M | 231.14M | 575.71M | 1.13B |
| Depreciation & Amortization | 9.17B | 7.88B | 6.56B | 5.95B | 2.97B | 1.96B | 1.75B | 1.58B | 1.29B |
| EBITDA | -3.88B | 5.37B | -23.29B | -52.51B | 2.67B | 3.30B | -2.74B | -4.54B | -406.82M |
| EBITDA Ratio | -5.59% | 7.42% | -1.69% | -0.05% | 38.64% | 29.21% | -27.21% | -110.03% | -89.52% |
| Operating Income | 7.70B | -3.77B | -7.23B | -5.96B | 9.81B | 5.31B | -4.89B | -6.91B | -2.72B |
| Operating Income Ratio | 11.10% | -6.79% | -18.36% | -20.93% | 29.66% | 21.34% | -42.32% | -142.71% | -169.81% |
| Total Other Income/Expenses | -22.31B | 430.46M | -23.59B | -54.63B | -10.44B | -4.02B | -366.99M | 211.65M | -106.48M |
| Income Before Tax | -14.61B | -3.02B | -30.70B | -60.60B | -628.12M | 1.30B | -4.72B | -6.70B | -2.83B |
| Income Before Tax Ratio | -21.07% | -5.44% | -77.94% | -212.69% | -1.90% | 5.21% | -40.76% | -138.34% | -176.46% |
| Income Tax Expense | 745.04M | 99.24M | -2.79B | -460.79M | 253.50M | -2.48B | 0.00 | 0.00 | -7.51M |
| Net Income | -13.88B | -1.10B | -27.57B | -60.13B | -881.62M | 3.78B | -4.72B | -6.70B | -2.83B |
| Net Income Ratio | -20.01% | -1.98% | -70.01% | -211.07% | -2.67% | 15.19% | -40.76% | -138.34% | -176.46% |
| EPS | -381.00 | -30.19 | -777.82 | -2.15K | -32.35 | 145.87 | -188.18 | -385.87 | -112.84 |
| EPS Diluted | -380.79 | -30.19 | -777.82 | -2.15K | -32.35 | 145.87 | -188.18 | -385.87 | -112.84 |
| Weighted Avg Shares Out | 36.43M | 36.40M | 35.45M | 28.02M | 27.25M | 25.92M | 25.06M | 17.37M | 25.06M |
| Weighted Avg Shares Out (Dil) | 36.45M | 36.40M | 35.45M | 28.02M | 27.25M | 25.92M | 25.06M | 17.37M | 25.06M |
Source: https://incomestatements.info
Category: Stock Reports